Biotechnology News

PASADENA, Calif., Jan. 26, 2026 (GLOBE NEWSWIRE) -- The power of artificial intelligence (AI) and advanced computing has made it possible to design genetic sequences encoding for diverse biological...

SAN DIEGO, Jan. 26, 2026 (GLOBE NEWSWIRE) -- Genyro Inc., a biotechnology company advancing next-generation DNA construction, today announced that it has entered into an exclusive licensing...

SAN DIEGO, Jan. 26, 2026 (GLOBE NEWSWIRE) -- Today, Primmune Therapeutics, a biotech company harnessing the power of the innate immune system, announced an additional close of its Series B financing...

LA JOLLA, Calif., Jan. 26, 2026 (GLOBE NEWSWIRE) -- Leios Therapeutics, a clinical-stage biotechnology company focused on innovative aesthetic therapies, today announced the execution of a licensing...

Topline data expected in 1Q 2028 Phase 2 bipolar depression trial initiation follows positive Phase 2 results in acute schizophrenia NEW YORK, Jan. 26, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals...

KØBENHAVN, Danmark, 26. januar 2026 – Bavarian Nordic A/S (OMX: BAVA) offentliggør transaktioner under aktietilbagekøbsprogrammet, der blev iværksat den 7. januar 2026, hvorunder selskaber vil...

COPENHAGEN, Denmark, January 26, 2026 – Bavarian Nordic A/S (OMX: BAVA) announces transactions under the share buy-back program launched on January 7, 2026, under which the Company will repurchase...

ALAMEDA, Calif., Jan. 25, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting...

If approved, LEQEMBI IQLIK would be the first and only anti-amyloid treatment to offer at-home injection options for initiation and maintenance dosing for this progressive, relentless disease FDA...

DURHAM, N.C. and NEW YORK, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Immunovant (Nasdaq: IMVT) today announced that it will report its financial results for the third quarter ended December 31, 2025, and...